curbside consult prostate cancer

Curbside Consult: Episode 4, Part 2

Why Did 5-ARIs Receive a Black Box Warning?

Herbert Lepor, MD, and Danil Makarov, MD, MHS discuss treating lower urinary track symptoms (LUTS). They explain why one of the treatments, 5-ARIs, are no longer approved for chemoprevention by the FDA.

Learn more about Herbert Lepor, MD.

Learn more about Danil V. Makarov, MD, MHS.

Faculty

Herbert Lepor

Herbert Lepor, MD

Martin Spatz Chariman of the Department of Urology

Professor of Urology

Professor of Pharmacology

Director, Smilow Comprehensive Prostate Cancer Center

NYU Langone Medical Center

Danil V. Makarov

Danil V Makarov, MD, MHS

Assistant Professor of Urology and Health Policy

Director, Division of Urological Health Services Research, Department of Urology

NYU Langone Medical Center